Synereca Pharmaceutics Raises $1.4M in Convertible Debt Financing

Synereca Pharmaceutics, Inc. (SPI), an Oklahoma City, OK-based research-stage biopharmaceutical company developing novel orally active drugs that restore or increase the effectiveness of existing antibiotics, raised $1.4m in convertible debt financing.

The round, of undisclosed amount, was led by Accele Venture Partners, with participation from i2E and private investors.

The company intends to use the funds to advance research focused on compounds to potentiate the effectiveness of existing antibiotics against drug-resistant Gram-negative bacteria.

Led by Clayton Duncan, acting CEO and Accele Biopharma CEO, Synereca has two lead research programs. The first focuses on compounds that potentiate the effectiveness of Colistin without enhancing toxicity, and a second program focusing on the inhibition of RecA, a key enzyme in bacterial DNA repair and the development and transmission of antibiotic resistance.



Join the discussion